# PATENT COOPERATION TREATY

# **PCT**

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Artcle 36 and Rule 70)

Applicant's or agent's file reference			
PCTA9501-1	FOR FURTHER AC		See Form PCT/IPEA/416
International application No. PCT/KR2005/000016	International filing date	· · ·	Priority date (day/month/year)
<del></del>	05 JANUARY 200		05 JANUARY 2004 (05.01.2004)
International Patent Classification (IP	C) or national classification	and IPC	
G01N 30/88(2006.01)i			
Applicant			
Bio-MED Photonics Co., Ltd	. èt al		
This report is the international p Authority under Article 35 and	oreliminary examination reportransmitted to the applicant	ort, established by this In according to Article 36.	ternational Preliminary Examining
2. This REPORT consists of a total	l of 6 sheets	, including this cover she	et.
3. This report is also accompanied	by ANNEXES, comprising	g:	
	nd to the International Bure		sheets, as follows: amended and are the basis for this report
and/or sheets co	ontaining rectifications author	orized by this Authority (	(see Rule 70.16 and Section 607 of the
sheets which su	persede earlier sheets, but w	which this Authority consi	ders contain an amendment that goes
beyond the disc Supplemental B	losure in the international ap	pplication as filed, as indi	cated in item 4 of Box No. I and the
b. (sent to the Internation	al Bureau only) a total of (i	ndicate type and number	of electronic carrier(s)),
containing a sequence Box relating to Sequence	listing and/or tables related ace Listing (see Section 802)	thereto, in electronic form	n only, as indicated in the Supplemental
4. This report contains indications	_	ms:	
Box No. I Basis of the	ie report		
Box No. II Priority			
· ·		gard to novelty, inventive	step and industrial applicability
	nity of invention	(2) with record to movelt	. Instanting the second of the second
citations a	nd explanations supporting	such statement	, inventive step or industrial applicability;
블	ocuments cited		
	fects in the international app	•	
Box No. VIII Certain ob	servations on the internation	nal application	
Date of submission of the demand		Date of completion of the	nis report
26 OCTOBER 2005	(26.10.2005)	29 MARCH 20	006 (29.03.2006) 24 1/2
· ·			A PARTY OF THE PAR
Name and mailing address of the IPEA  Korean Intellectual Proper		Authorized officer	Toron & Section
920 Dunsan-dong, Seo-gu Republic of Korea	, Daejeon 302-701,	PARK, JEONG U	NG
Facsimile No. 82-42-472-7140		Telephone No. 82-42-4	481-8159 包
			C. Minming ()

International application No.
PCT/KR2005/000016

Box No.	. I Basis of the report		
1. Wi	ith regard to the language, this report is based on the inte	rnational application in the lan	guage in which it was filed, unless
oth	nerwise indicated under this item.		
$\boxtimes$		language into the following language	nguage <u>English</u>
	which is the language of a translation furnished for th		
	international search (under Rules 12.3 and 23.1		
	publication of the international application (un	der Rule 12.4)	
	international preliminary examination (under R	Rules 55.2 and/or 55.3)	
to ti	th regard to the <b>elements</b> of the international application, the receiving Office in response to an invitation under Art nexed to this report):  the international application as originally filed/furnished the description:	ticle 14 are rejerred to in this r	eori as originally flea and are not
	pages 1-110, 112-116	· · · · · · · · · · · · · · · · · · ·	as originally filed/furnished
	pages* 111	eceived by this Authority on eceived by this Authority on	04 April 2005
×	the claims:		
<u> </u>	pages 117-129		as originally filed/furnished er with any statment) under Article 19
	pages*r	as amended (togeth	er with any standenty under Article 19
	pages*I	eceived by this Authority on	
	pages*r	outries of minimum of the	
	the drawings:	•	
_	noges 1/12-1/12 \	ived by this Authority ca	as originally filed/furnished
	pages*pages*	received by this Authority on	
3. [	the sequence listing and/or any related table(s) - see S  The amendments have resulted in the cancellation of the description, pages the claims, Nos.  the drawings, sheets the sequence listing (specify):  any table(s) related to sequence listing (specify)	f:	
4.	This report has been established as if (some of) the a made, since they have been considered to go beyond (Rule 70.2(c)).  the description, pages the claims, Nos. the drawings, sheets the sequence listing (specify): any table(s) related to sequence listing (specify)	the disclosure as filed, as indi	cated in the Supplemental Box
* If	item 4 applies, some or all of those sheets may be market	d "superseded."	

International application No. PCT/KR2005/000016

В	ox No.	IV Lack of unity of invention
1.		In response to the invitation to restrict or pay additional fees the applicant has, within the applicable time limit:  restricted the claims  paid additional fees  paid additional fees under protest and, where applicable, the protest fee
		paid additional fees under protest but the applicable protest fee was not paid
		neither restricted nor paid additional fees.
2.	· 🔀	This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.
3.	This	Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is:
		complied with.
		not complied with for the following reasons:
		The common concept linking together the independent Claims 1, 5 & 9 is the following:
		including (a) a fluorescently-labeled detector reacts with analyte in liquid sample forming the fluorescently-labeled detector/analyte complex; (b) an unlabeled captor immobilized on the chromatographic medium reacts with the said complex forming the fluorescently-labeled detector/analyte/unlabeled captor triple complex; (c) a fluorescently-labeled reference detector reacts with a reference material in the liquid sample forming a reference complex and the complex further reacts with an unlabeled reference captor forming a reference triple complex; and (d) the amount of analytes is quantified by a laser-induced epifluorescence detection device as the fluorescence intensity of the triple complex of the analyte is being compared with that of the reference complex
		Group I: Claims 1-11 The said common concept is apparently neither novel nor inventive. See under Box V.
	`	Group II: Claims 12, dependent on Claim 9. features the window wall having a slope of 20 degree.
		Group III: Claims 14 & 15, dependent on Claim 9, feature a time reading window on top plate of the cartridge housing.
		The requisite unity of invention (Rule 13.1 PCT) therefore no longer exists between said Groups as far as a single inventive concept within the meaning of Rule 13.2 does not exist between Groups I-III.
4.		equently, this report has been established in respect of the following parts of the international application: all parts. the parts relating to claims Nos.

International application No.

PCT/KR2005/000016

# Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement			
Novelty (N)	Claims	2, 3, 6, 7, 10 & 12-15	YE
	Claims	1, 4, 5, 8, 9 & 11	
Inventive step (IS)	Claims	12, 14 & 15	YE
	Claims	1-11 & 13	NC
Industrial applicability (IA)	Claims	1-15	YE
·	Claims	none	NO

## 2. Citations and explanations (Rule 70.7)

Reference is made to the following documents from the International Search Report (ISR):

D1: WO 03062824 A1 D2: US 6136549 A D3: US 5705338 A

Object of the present invention is to provide a method (Claim 1) and a strip (Claim 5) for the detection of lateral flow assay and a scanner (Claim 9) integrated with a laser-induced epifluorescence detection device.

#### 1. Novelty

(i) regarding Claims 1, 4, 5, 8, 9 & 11

The subject matter of the present invention comprises constituents as recited in Claim 1 featuring a sandwich immunochromatographic method, which includes (a) a fluorescently-labeled detector reacts with analyte in liquid sample forming the fluorescently-labeled detector/analyte complex; (b) an unlabeled captor immobilized on the chromatographic medium reacts with the said complex forming the fluorescently-labeled detector/analyte/unlabeled captor triple complex; (c) a fluorescently-labeled reference detector reacts with a reference material in the liquid sample forming a reference complex and the complex further reacts with an unlabeled reference captor forming a reference triple complex; and (d) the amount of analytes is quantified by a laser-induced epifluorescence detection device as the fluorescence intensity of the triple complex of the analyte is being compared with that of the reference complex. The subject matters of Claims 5 & 9 also feature the aforementioned constituents.

D1 is considered the most relevant state of the art of the present invention in providing a lateral flow quantitative immunochromatography assay method, a strip and a detection means. D1 describes all the constituents of the subject matters of Claims 1, 5 & 9 (see in claims 1,8,18 & 30 of D1). D1 thus appears a novelty-destroying prior art. Claims 4, 8 & 11, which are dependent on Claims 1,5 & 9 respectively, are also disclosed in claims 4, 11 & 21 of D1 and therefore lack novelty.

Consequently, Claims 1, 4, 5, 8, 9 & 11 fail to fulfill the requirements set out in Article 33(2) PCT.

— continued in Supplemental box

International application No.

PCT/KR2005/000016

### Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Box No. V

(ii) regarding Claims 2, 3, 6, 7, 10 & 12-15

Claims 3, 7 & 10 limit the unlabeled reference captor of Claims 1,5 & 9 to anti-mouse IgG, whereas use of anti-rabbit IgG is only disclosed in D1.

The dependent Claims 2, 6 & 12-15 impart the additional limitations to the subject matters of Claims 1,5 & 9, which are neither indicated in D1 nor directly inferred from the prior art.

Accordingly, Claims 2, 3, 6, 7, 10 & 12-15 meet the requirements set forth in Article 33(2) PCT.

### 2. Inventive step

(i) regarding Claims 1, 3-5 & 7-11

If novelty should be disputed based on some minor difference of interpretation, it is pointed out that the subject matter of Claims 1, 4, 5, 8, 9 & 11 would in any case not involve an inventive step. Because only slight modifications in constituents of said claims appear either to come within the scope of the customary practice followed by skilled persons in the art or to be what is easily achievable from the combination of D1 & D2, especially as the advantages thus achieved can readily be foreseen.

D2 discloses a system and a method for a lateral flow assay, wherein a test strip is analyzed by a photometer comprising a light source such as laser diodes and a fluorescence photodetector. Although D2 is directed to a magnetic chromatography assay method, which is alternative to the conventional assay system, D2 describes all the features of the conventional sandwich assay system, which constitute the subject matter of Claims 1, 5 & 9 (see in column 1, line 47 ~ column 5, line 11; column 11, line 23 ~ column 12, line 38; column 13, lines 18 ~ 67; and Figures 3a & 3b).

Regarding Claims 3, 7 & 10, it is believed that use of anti-mouse IgG as either captor or detector falls within the customary practice in the art and is thus obvious to a skilled person in the art. Furthermore, it is easily derivable from the combination of D1 & D2.

Therefore, Claims 1, 3-5 & 7-11 fail to fulfill the requirements set out in Article 33(3) PCT for the lack of inventive step.

## (ii) regarding Claims 2, 6 & 13

Claims 2, 6 & 13 add to subject matter of Claims 1, 5 & 9, respectively, an immobilized Ag (Which is unclear but interpreted as antigen or analyte in this report) line, with which Ag or a detector reacts, taking into account the Hook effect. That is also considered a problem to be solved of D3. D3 indicates that the second zone containing an analyte derivative traps unreacted labeled specific binder only, and it thus corresponds to the Ag line of the present claims (see column 3, line  $55 \sim$  column 4, line 19 and claims 6 & 7 in D3). Therefore, it is obvious to a person skilled in the art to arrive at the claimed invention through combining what D1 & D3 teach without exercising an inventive step. The advantage thus achieved is also foreseen.

Accordingly, Claims 2, 6 & 13 do not meet the criteria set forth in Article 33(3) PCT.

- continued in Supplemental box

International application No.

PCT/KR2005/000016

### Supplemental Box

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Box V & Supplemental box

(iii) regarding Claims 12, 14 & 15

Claim 12 is about the scanner featuring the window wall having a slope of 20 degree.

Claims 14 & 15 are about the scanner featuring a time reading window on top plate of the cartridge housing.

The technical features are neither indicated nor suggested in prior art documents. It is unlikely to arrive at the claimed inventions even by combination of teachings from prior art unless exercising an inventive step. Advantages thus achieved in the present claims such as decreasing noise and variations in accuracy are considered unforseen over prior art.

Therefore, Claims 12, 14 & 15 meet the criteria set forth in Article 33(3) PCT.

3. Industrial applicability

Object of Claims 1-15 is to provide a method and a strip for the detection of lateral flow assay and a scanner, which are considered industrial applicable. Consequently, Claims 1-15 meet the requirements of Article 33(4) PCT.